Acquired resistance to sunitinib in human renal cell carcinoma cells is mediated by constitutive activation of signal transduction pathways associated with tumour cell proliferation

BJU International

Volumn 112, Issue 2, 2013, Pages

  Sakai, Iori ^a   Miyake, Hideaki ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

angiogenesis; renal cell carcinoma; resistance; signal transduction pathway; sunitinib

Indexed keywords

EVEROLIMUS; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE; SUNITINIB; TEMSIROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL PROLIFERATION; CELL STRAIN ACHN; CELL TYPE; CONTROLLED STUDY; CROSS RESISTANCE; DOWN REGULATION; DRUG EXPOSURE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; KIDNEY CARCINOMA; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NICK END LABELING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; PYRROLES; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84879686616     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11655.x     Document Type: Article

References (32)

1. Rini BI, Rathmell WK, Godley P,. Renal cell carcinoma. Curr Opin Oncol 2008; 20: 300-316
2. Motzer RJ, Bacik J, Schwartz LH, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22: 454-463
3. Herrmann E, Bierer S, Wülfing C,. Update on systemic therapies of metastatic renal cell carcinoma. World J Urol 2010; 28: 303-309
4. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M,. Interferon-α as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2005; 20: 289-296
5. Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M,. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol Oncol 2009; 27: 598-603
6. Bellmunt J, Montagut C, Albiol S, Carles J, Maroto P, Orsola A,. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents. BJU Int 2007; 99: 274-280
7. Chowdhury S, Larkin JM, Gore ME,. Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 2008; 44: 2152-2162
8. Gan HK, Seruga B, Knox JJ,. Sunitinib in solid tumors. Expert Opin Investig Drugs 2009; 18: 821-834
9. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337
10. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27: 3584-3590
11. Rini BI, Atkins MB,. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 2009; 10: 992-1000
12. Bhatt RS, Wang X, Zhang L, et al. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther 2010; 9: 2793-2802
13. Hammers HJ, Verheul HM, Salumbides B, et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study. Mol Cancer Ther 2010; 9: 1525-1535
14. Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010; 70: 1063-1071
15. Kumano M, Miyake H, Kurahashi T, Yamanaka K, Fujisawa M,. Enhanced progression of human prostate cancer PC3 cells induced by the microenvironment of the seminal vesicle. Br J Cancer 2008; 98: 356-362
16. Terakawa T, Miyake H, Furukawa J, Ettinger SL, Gleave ME, Fujisawa M,. Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells. Br J Cancer 2009; 101: 1731-1739
17. Miyake H, Muramaki M, Kurahashi T, et al. Expression of clusterin in prostate cancer correlates with Gleason score but not with prognosis in patients undergoing radical prostatectomy without neoadjuvant hormonal therapy. Urology 2006; 68: 609-614
18. Guix M, Faber AC, Wang SE, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 2008; 118: 2609-2619
19. Muramaki M, So A, Hayashi N, et al. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int 2009; 103: 384-390
20. Di Lorenzo G, Buonerba C, Federico P, et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol 2010; 58: 906-911
21. Okabe T, Okamoto I, Tsukioka S, et al. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification. Clin Cancer Res 2009; 15: 907-913
22. Di Nicolantonio F, Arena S, Tabernero J, et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 2010; 120: 2858-2866
23. Peng DJ, Wang J, Zhou JY, Wu GS,. Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun 2010; 394: 600-605
24. Donev IS, Wang W, Yamada T, et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res 2011; 17: 2260-2269
25. Jiang X, Borgesi RA, McKnight NC, Kaur R, Carpenter CL, Balk SP,. Activation of nonreceptor tyrosine kinase Bmx/Etk mediated by phosphoinositide 3-kinase, epidermal growth factor receptor, and ErbB3 in prostate cancer cells. J Biol Chem 2007; 282: 32689-32698
26. Plaza-Menacho I, Morandi A, Robertson D, et al. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 2010; 29: 4648-4657
27. Hoare S, Hoare K, Reinhard MK, Lee YJ, Oh SP, May WS Jr,. Tnk1/Kos1 knockout mice develop spontaneous tumors. Cancer Res 2008; 68: 8723-8732
28. Roskoski R Jr,. Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun 2007; 356: 323-328
29. Welti JC, Gourlaouen M, Powles T, et al. Fibroblast growth factor 2 regulates endothelial cell sensitivity to sunitinib. Oncogene 2011; 30: 1183-1193
30. van Cruijsen H, van der Veldt A, Hoekman K,. Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions. Front Biosci 2009; 14: 2248-2268
31. Larkin J, Swanton C, Pickering L,. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Rev Anticancer Ther 2011; 11: 639-649
32. Tamaskar I, Dhillon J, Pili R,. Resistance to angiogenesis inhibitors in renal cell carcinoma. Clin Adv Hematol Oncol 2011; 9: 101-110